Viatris (VTRS) Amortization of Goodwill (2023 - 2025)

Viatris' (VTRS) quarterly Amortization of Goodwill came in at $2.9 billion in Q1 2025, up 814.89% quarter-over-quarter from $321.0 million in Q2 2024.

Viatris (VTRS) Amortization of Goodwill (2023 - 2025) Analysis & Trends

Viatris' Amortization of Goodwill history runs 3 years deep, the most recent figure standing at $2.9 billion for Q1 2025.

  • On a quarterly basis, Amortization of Goodwill changed N/A year-over-year to $2.9 billion in Q1 2025; TTM through Dec 2025 was $2.9 billion, a 814.89% increase from a year earlier, with the FY2025 full-year figure at $2.9 billion, up 814.89% from the prior year.
  • Amortization of Goodwill grew to $2.9 billion in Q1 2025 per VTRS's latest filing, from $321.0 million in the prior quarter.
  • Across five years, Amortization of Goodwill topped out at $2.9 billion in Q1 2025 and bottomed at $321.0 million in Q2 2024.
  • The 3-year median for Amortization of Goodwill is $580.1 million (2023), against an average of $1.3 billion.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2025 2.94 Bn
Mar 31, 2025 2.94 Bn
Jun 30, 2024 321.00 Mn
Jun 30, 2024 321.00 Mn
Dec 31, 2023 580.10 Mn
Dec 31, 2023 580.10 Mn